ClinicalTrials.gg
RecruitingNCT07705438Updated Jul 15, 2026

Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC

An observational study in Triple Negative Breast Cancer, Immune Checkpoint Inhibitor and Granzyme B PET/CT, sponsored by Fudan University. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Fudan University · Observational

How we know · 2 judgments

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Triple Negative Breast Neoplasms by Fudan University — 35 open to participants now, 39 under way, 12 of them phase 3. Triple Negative Breast Neoplasms · Fudan University.

Started
2025
with 6 others
Observational
3 of 65
3 open now
Primary completion
2027-05
later than 19 of 38 live
Registered
57th of 65
by date

Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, this one is one of 7 that started in 2025, is one of 3 observational ones, reaches primary completion later than 19 of the 38 other live ones, and was the 57th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 65 studies in Triple Negative Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

Where they have run

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Triple Negative Breast Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This study plans to enroll 30 patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are scheduled to receive at least two cycles of a regimen containing an immune checkpoint inhibitor (ICI). All ICI treatments must be administered in accordance with current clinical indications. For patients who intend to participate in a clinical trial involving an ICI, they must meet the eligibility criteria of that specific trial protocol.

After screening and enrollment, participants will undergo a [68Ga]Ga-DOTA-GSI PET/CT (Granzyme B PET/CT) scan before initiating the ICI-containing regimen and again after Cycle 2 (C2). Participants will continue the ICI regimen until disease progression, with tissue biopsies performed as needed.

By integrating patients' baseline clinical characteristics, treatment outcomes, and prognostic information, this study aims to conduct a comprehensive analysis. The objective is to investigate whether the following factors, as assessed by Granzyme B PET/CT, can serve as early predictors of response to immunotherapy in patients with advanced breast cancer: baseline Granzyme B expression levels, immunotherapy-activated Granzyme B levels after C2, and the heterogeneity of Granzyme B expression at baseline and after C2.

03

Conditions studied

  • Triple Negative Breast Cancer
  • Immune Checkpoint Inhibitor
  • Granzyme B PET/CT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Locally advanced or metastatic triple-negative breast cancer patients scheduled to receive at least two cycles of an immune checkpoint inhibitor (ICI)-containing regimen

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. confirmed unresectable locally advanced or breast cancer, with immunohistochemistry (IHC) results indicating negativity for ER, PR, and Her-2. If pathology from a metastatic lesion is available, its histology will take precedence.

    ER and PR negativity is defined as: ER \<1% positive and PR \<1% positive, OR ER \<10% with weak positivity and PR \<10% with weak positivity.

    Her-2 negativity is defined as: an IHC score of 0 or 1+; or an IHC score of 2+ with a negative FISH test result. For patients with an IHC score of 0 or 1+, a FISH test is optional but must be negative if performed.

  3. Decision by the clinician to treat with a regimen containing an (ICI), with the patient scheduled to receive at least 2 cycles of treatment.

    3.1. If the patient intends to participate in an ongoing clinical trial involving an ICI at our department, they must meet the inclusion and exclusion criteria of that specific trial. ICIs involved in clinical trials at our department include, but are not limited to, Pembrolizumab, Sintilimab, Toripalimab, and QL1706.

    3.2. For patients not enrolled in a clinical trial, they must have PD-L1 positive status (CPS ≥ 1), and the intended drug must be Toripalimab, as approved by the National Medical Products Administration (NMPA).

  4. (ECOG) performance status of 0 or 1.
  5. Evidence of radiological or objective disease progression during or after the most recent systemic therapy prior to study entry, or intolerance to the toxicity of prior treatment.
  6. of ≥ 12 weeks at the time of screening.
  7. Presence of at least one that has not been previously irradiated. The lesion must have a longest diameter of ≥10 mm at baseline as measured by CT or MRI (for lymph nodes, the short axis must be ≥15 mm). In cases where only bone lesions are present, lytic or mixed lytic-blastic bone lesions that can be assessed by CT, MRI, or X-ray are acceptable.
  8. (LVEF) ≥ 50% within 28 days prior to randomization.
  9. Adequate organ and bone marrow function within 14 days prior to randomization. The most recently obtained results for all parameters listed below must be used to meet the eligibility criteria:

    1. ≥ 9 g/dL
    2. (ANC) ≥ 1,500/mm³
    3. count ≥ 100,000/mm³
    4. At baseline, Total (TBL) ≤ 1.5 × (ULN) if no liver metastases are present, or \< 3 × ULN for patients with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases.
    5. and AST ≤ 3 × ULN, or \< 5 × ULN for patients with liver metastases.
    6. Serum albumin ≥ 2.5 g/dL
    7. ≥ 30 mL/min (calculated using the Cockcroft-Gault formula).
    8. (INR) or Prothrombin Time (PT), and Partial Thromboplastin Time (PTT) or activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN.
  10. From the screening period through the entire study treatment period and for 7 months after the last dose of study treatment, female patients must not donate or retrieve oocytes (eggs) for personal use. Breastfeeding must be avoided during this period. If oocyte preservation is desired, it should be completed prior to randomization in this study.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled concomitant diseases, including but not limited to: persistent or active infection; uncontrolled or significant cardiovascular disease; severe chronic gastrointestinal conditions associated with diarrhea; or psychiatric/social conditions that may limit compliance with study requirements, significantly increase the risk of adverse events (AEs), or impair the patient's ability to provide written .
  2. Uncontrolled or significant cardiovascular disease, including any of the following:

    1. History of myocardial infarction or symptomatic Congestive Heart Failure (CHF) ( [NYHA] Class II to IV) within 6 months prior to randomization. Patients with troponin levels above the (ULN) (as defined by the manufacturer) at screening without any symptoms related to myocardial infarction should undergo a cardiology consultation prior to randomization to rule out myocardial infarction.
    2. Uncontrolled hypertension.
    3. Uncontrolled and/or arrhythmias.
  3. History of (non-infectious) interstitial lung disease (ILD)/pneumonitis requiring treatment, current ILD/pneumonitis, or suspected ILD/pneumonitis on imaging at screening that cannot be ruled out.
  4. Use of medications within 14 days prior to the first dose of the study drug, with the exception of intranasal and inhaled corticosteroids, or systemic corticosteroids at a dose of less than 10 mg/day of prednisone or its equivalent.
  5. Clinically significant pulmonary-specific comorbidities, including but not limited to any underlying pulmonary disease (e.g., pulmonary embolism within three months prior to randomization, severe asthma, severe [COPD], restrictive lung disease, significant pleural effusion), and/or any , connective tissue, or inflammatory diseases with concomitant pulmonary involvement (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis), and/or prior lung resection.
  6. Uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals.
  7. Spinal cord compression or clinically active central nervous system (CNS) , defined as untreated and symptomatic, or requiring corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive may be eligible. Subjects may be included if their brain metastases have been treated, they are no longer symptomatic, do not require corticosteroids or anticonvulsants, and have recovered from the acute toxic effects of radiotherapy.
  8. Active primary immunodeficiency, known (HIV) infection, or active or infection. For patients with positive Hepatitis C antibody, only those who are negative for HCV RNA by polymerase chain reaction (PCR) are eligible for enrollment.
  9. Unresolved toxicity from prior anticancer therapy, defined as toxicity that has not resolved to ≤ Grade 1 or baseline (with the exception of alopecia).

    Note: Subjects with chronic, stable Grade 2 toxicity (defined as not having worsened for at least 3 months prior to enrollment and being manageable with standard therapy) that the investigator deems related to prior anticancer therapy may be enrolled. Examples include chemotherapy-induced neuropathy or fatigue; residual toxicity from prior immunosuppressive therapy such as Grade 1 or 2 endocrinopathy.

  10. Female patients who are pregnant or breastfeeding, or are planning to become pregnant.
  11. Known history of severe reaction to the active substance, in the drug formulation, or other monoclonal antibodies.
  12. History of another primary within the last 3 years, with the exception of: adequately resected non-melanoma skin cancer, curatively treated carcinoma in-situ, other solid tumors that have been cured, or contralateral breast cancer.
  13. Substance abuse or any other medical condition, such as a psychiatric illness, that in the investigator's judgment could interfere with the patient's participation in or the evaluation of the results of the clinical study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Interventions

  • Other[68Ga]Ga-DOTA-GSI PET/CT (Granzyme B PET/CT)

    Granzyme B is a highly specific cytotoxic molecule. By binding to Granzyme B, Granzyme B-PET can visualize the distribution and activity of this enzyme within the tumor microenvironment on PET images. Performing Granzyme B-PET scans before and after immunotherapy allows for the monitoring of changes in active intratumoral immune cells during treatment. This, in turn, helps to assess whether the therapy has effectively activated the immune system and the extent of tumor cell killing. Granzyme B-PET images provide a measure of intratumoral Granzyme B uptake, thereby enabling an objective evaluation of the cytotoxic capacity of immune cells.

06

What researchers measure

Primary outcomes

  1. Positive Predictive Value (PPV)

    Positive Predictive Value of Granzyme B Expression as Assessed by Granzyme B PET/CT for Objective Response.

    Time frame: Up to disease progression, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2025
First posted
Jul 15, 2026
StartActual
May 28, 2025
Primary completionEst.
May 28, 2027
CompletionEst.
May 28, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07705438
Lead sponsor
Fudan University
Responsible party
Hongxia Wang (Director of Medical Oncology, Fudan University) — Principal investigator
First posted
Jul 15, 2026
Start date
May 28, 2025
Primary completion
May 28, 2027 (estimated)
Completion
May 28, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Juan Jin, Attending physician
Contact
medjinjuan@126.com
15996290233

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion